MSC-Derived Wound Repair Composition With High EV and Growth Factor Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for enhancing the secretion of extracellular vesicles and growth factors from mesenchymal stem cells are inadequate for effective treatment of specific diseases, failing to increase the concentration of these components sufficiently.
Innovation Solution
A pharmaceutical composition is prepared by culturing human mesenchymal stem cells in a serum-free medium containing specific growth factors, redox substances, and energy metabolism-related ingredients, followed by purification and refining to obtain a composition rich in extracellular vesicles, insulin, and multiple growth factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If physical stimulation or external pressure is applied to mesenchymal stem cells to enhance secretion of EVs or growth factors, then the secretion amount increases, but the concentration of effective ingredients for treating specific diseases does not increase
Solution Approach 1:
The patent changes the chemical parameters of the culture medium by replacing serum-containing medium with a defined serum-free medium containing specific growth factors (bFGF, EGF, HGF), redox substances (glutathione, catalase), and energy metabolism ingredients. This parameter change transforms the secretion profile to produce higher concentrations of disease-effective ingredients without relying on physical stimulation
Solution Approach 2:
The patent introduces specific growth factors (bFGF, EGF, HGF) as intermediary substances that mediate the interaction between the culture medium and mesenchymal stem cells. These intermediaries trigger specific signaling pathways that enhance the secretion of therapeutic EVs and growth factors with higher effective ingredient concentrations
2Productivity
If serum-containing medium is used for cell culture, then cell growth is supported, but the purity and effectiveness of the pharmaceutical composition for specific disease treatment is reduced
Solution Approach 1:
The patent extracts and removes serum from the culture medium, replacing it with a defined serum-free formulation. This extraction eliminates unwanted serum components (lipids, proteins, hormones) that would contaminate the final pharmaceutical product, thereby improving purity while maintaining cell growth through alternative growth factors
Solution Approach 2:
The patent applies local quality by providing specific growth factors, redox substances, and energy metabolism ingredients at optimized concentrations tailored for therapeutic EV production. Each component is precisely formulated to achieve both cell growth and high-purity pharmaceutical composition, rather than using generic serum
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly enhances the concentration of extracellular vesicles and growth factors, providing effective treatment for wound healing and various medical conditions, including diabetic wounds, neurodegenerative diseases, and cardiovascular diseases.
Implementation Method 1
the ingredients in the conditioned medium after MSC culture contain growth factors or extracellular vesicles (EVs), and these ingredients can be used for the treatment and application of the aforementioned indications
Implementation Method 2
treating the pharmaceutically effective mother liquor by a purification and refining means to obtain a pharmaceutical composition suitable for treating wound repair
Data Source
AI summary
The present invention can provide a pharmaceutical composition for treating wound repair and a preparation method thereof. The pharmaceutical composition at least includes an extracellular vesicle, insulin, and a plurality of growth factors, wherein the concentration of the extracellular vesicle in the pharmaceutical composition is (57.53±3.79)×108 particles/mL; the concentration of the insulin in the pharmaceutical composition is 34,870.83±7,335.13 mU/L; these growth factors are ANGPTL4, HGF, G-CSF, PDGF-AA, VEGF-A, IL-18BPa, COMP, MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-10, and MMP-12; and the extracellular vesicle contains a CLU protein, a TIMP1 protein and a YWHAB protein.